title: High efficiency targeting of IFN-α activity: possible applications in fighting tumours and infections.
abstract: In this short review, we summarize how insights into the structure and dynamics of interferon-receptor complex assembly and activation guided the design of a novel class of engineered type I interferons that combine a largely lost potency on non-targeted cells with high activity on targeted cells. These novel interferons are expected to exhibit lower systemic toxicities compared to other interferon therapy modalities and could open avenues to revive these cytokines for the treatment of patients suffering of cancer and viral infections.
authors.affiliation: CNRS UMR 5235, University Montpellier, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France. Electronic address: uze@univ-montp2.fr.
authors.forename: Gilles
authors.initials: G
authors.lastname: Uzé
authors.affiliation: Department of Medical Protein Research, Flanders Institute for Biotechnology, Ghent University, Faculty of Medicine and Health Sciences, Ghent, BE 9000, Belgium. Electronic address: jan.tavernier@vib-ugent.be.
authors.forename: Jan
authors.initials: J
authors.lastname: Tavernier
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D017471:Receptors, Interferon / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D014777:Virus Diseases / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D016898:Interferon-alpha; D017471:Receptors, Interferon; D011994:Recombinant Proteins
keywords: Antibody; Immunocytokine; Interferon; Receptor